Showing results (311-320 of 369) with videos related to
Sort By:
Pageof 37
European Heart Journal|May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialSafia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.European Journal of Heart Failure|May 22, 2023
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trialSafia Chatur, Jonathan W Cunningham, Muthiah Vaduganathan, et al.Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.Journal of the American College of Cardiology|December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection FractionMikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.Circulation. Heart Failure|August 27, 2022
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER TrialAlexander Peikert, Felipe A Martinez, Muthiah Vaduganathan, et al.European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.Journal of the American College of Cardiology|August 27, 2023
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal FunctionSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.Pageof 37